|  |  |  |  |
| --- | --- | --- | --- |
| Порядковый номер | Название | Название на английском | Ссылка |
| 1 | Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 2018;62:29–39. | - | DOI: 10.1016/j.intimp.2018.06.001. |
| 2 | Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019;2:e192535. | - | DOI: 10.1001/jamanetworkopen.2019.2535. |
| 3 | Common terminology criteria for adverse events (CTCAE) V5. Available | - | https://ctep.cancer.gov/protocolDevelopment/  electronic\_applications/ctc.htm |
| 4 | Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. International Journal of Cancer 2019;145:639–48. | - | Doi:10.1002/ijc.32132 |
| 5 | Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem (2019) 26:3009–25. | -- | doi: 10.2174/0929867324666170804143706 |
| 6 | Wang J, Yang T, Xu J. Therapeutic development of immune checkpoint inhibitors. Adv Exp Med Biol (2020) 1248:619–49 | - | doi: 10.1007/978-981-15-3266-5\_23 |
| 7 | Willsmore ZN, Coumbe B, Crescioli S, Reci S, Gupta A, Harris RJ, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol (2021) 51:544–56 | - | doi: 10.1002/eji.202048747 |
| 8 | Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 16:275–87 | - | doi: 10.1038/nrc.2016.36 |
| 9 | Cuyas E, Verdura S, Martin-Castillo B, Alarcon T, Lupu R, Bosch-Barrera J, et al. Tumor cell-intrinsic immunometabolism and precision nutrition in cancer immunotherapy. Cancers (Basel) (2020) 12(7):1757. | - | doi: 10.3390/cancers12071757 |
| 10 | Lim S, Phillips JB, Madeira DSL, Zhou M, Fodstad O, Owen LB, et al. Interplay between immune checkpoint proteins and cellular metabolism. Cancer Res (2017) 77:1245–9 | - | doi: 10.1158/0008-5472.CAN-16-1647 |
| 11 | Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol (2021) 14:45. | - | doi: 10.1186/s13045-021-01056-8 |
| 12 | Barclay J, Creswell J, Leon J. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Arch Esp Urol (2018) 71:393–9. | - | PMID: 29745928 |
| 13 | Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J (2021) 23:39. |  | doi: 10.1208/s12248-021-00574-0 |
| 14 | Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (2018) 359:1350–5. |  | doi: 10.1126/science.aar4060 |
| 15 | Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer (2019) 18:10. |  | doi: 10.1186/s12943-018-0928-4 |
| 16 | Liao D, Wang M, Liao Y, Li J, Niu T. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol (2019) 10:609. |  | doi: 10.3389/fphar.2019.00609 |
| 17 | Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 1:32–42. |  | doi: 10.1158/2326-6066.CIR-13-0013 |
| 18 | Waight JD, Chand D, Dietrich S, Gombos R, Horn T, Gonzalez AM, et al. Selective FcgammaR Co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell (2018) 33:1033–47. |  | doi: 10.1016/j.ccell.2018.05.005 |
| 19 | Qi Y, Chen L, Liu Q, Kong X, Fang Y, Wang J. Research progress concerning dual blockade of lymphocyte-activation gene 3 and programmed death-1/Programmed death-1 ligand-1 blockade in cancer immunotherapy: preclinical and clinical evidence of this potentially more effective immunotherapy strategy. Front Immunol (2020) 11:563258. | - | doi: 10.3389/fimmu.2020. |
| 20 | Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fernandez-Rubio L, et al. Understanding LAG-3 signaling. Int J Mol Sci (2021) 22(10):5282. | - | doi: 10.3390/ijms22105282 |
| 21 | Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol (2011) 186:5173–83. |  | doi: 10.4049/jimmunol.1002050 |
| 22 | Lythgoe MP, Liu D, Annels NE, Krell J, Frampton AE. Gene of the month: lymphocyte-activation gene 3 (LAG-3). J Clin Pathol (2021) 74:543–7. | - | doi: 10.1136/jclinpath-2021-207517 |
| 23 | Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol (2021) 14:147. | - | doi: 10.1186/s13045-021-01161-8 |
| 24 | Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res (2014) 74:3418–28. | - | doi: 10.1158/0008-5472.CAN-13-2690 |
| 25 | Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res (2015) 3:412–23. | - | doi: 10.1158/2326-6066.CIR-14-0150 |
| 26 | Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (2016) 353(6307):aah3374. | - | doi: 10.1126/science.aah3374 |
| 27 | Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, et al. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. Sci Rep (2015) 5:15659. | - | doi: 10.1038/srep15659 |
| 28 | Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol (2018) 62:29–39. | - | doi: 10.1016/j.intimp.2018.06.001 |
| 29 | Rocha M, Correia DSJ, Salgado M, Araujo A, Pedroto I. Management of gastrointestinal toxИКТty from immune checkpoint inhibitor. GE Port J Gastroenterol (2019) 26:268–74. | - | doi: 10.1159/000494569 |
| 30 | Davies M, Duffield EA. Duffield EA: safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther 2017;6:51–71. | - | DOI: 10.2147/ITT.S141577 |
| 31 | Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (dire) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. Journal for ImmunoTherapy of Cancer 2019;7:165. doi: 10.1186/s40425-019-0645-6 | - | doi: 10.1186/s40425-019-0645-6 |
| 32 | Duma N, Lambertini M. It is time to talk about fertility and immunotherapy. Oncologist 2020;25:277–8. | - | doi:10.1634/theoncologist.2019-0837 |
| 33 | Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016;19:82–92. | - | doi:10.1007/s11102-015-0671-4 |
| 34 | Andrade Vila JH, da Silva JP, Guilhen CJ, et al. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. Transplantation 2008;86:369–70. | - | doi:10.1097/TP.0b013e31817cf28a |
| 35 | Merlob P, Stahl B, Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol 2009;28:105–8. | - | doi:10.1016/j.reprotox.2009.02.007 |
| 36 | Burotto M, Gormaz JG, Samtani S, et al. Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Semin Oncol 2018;45:164–9. | - | DOI: 10.1053/j.seminoncol.2018.03.003 |
| 37 | Xu W, Moor RJ, Walpole ET, et al. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res 2019;29:333–7. |  | Doi: 10.1097/CMR.0000000000000586 |
| 38 | Bucheit AD, Hardy JT, Szender JB, et al. Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition. Melanoma Res 2020;30:423–5. |  | Doi:10.1097/CMR.0000000000000657 |
| 39 | Butterfield LH, Kaufman HL, Johnson DH. SITC’s Guide to Managing Immunotherapy Toxicity, 1 edn. New York: Springer Publishing Company, 2019 |  | https://scholar.google.com/scholar\_lookup?title  =SITC’s%20Guide%20to%20Managing%  20Immunotherapy%20Toxicity,%2  01%20edn&publication\_year=2019& |
| 40 | Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of Corticosteroid-Associated adverse events: a systematic literature review. Clin Ther 2011;33:1413–32. |  | Doi:10.1016/j.clinthera.2011.09.009 |
| 41 | Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol (2018) 4:1721–8. |  | doi: 10.1001/jamaoncol.2018.3923 |
| 42 | Geisler AN, Phillips GS, Barrios DM, Wu J, Leung D, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol (2020) 83:1255–68. | - | doi: 10.1016/j.jaad.2020.03.132 |
| 43 | Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol (2021) 85:956–66. | - | doi: 10.1016/j.jaad.2020.09.054 |
| 44 | Nadelmann ER, Yeh JE, Chen ST. Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review. JAMA Oncol (2022) 8:130–8. | - | doi: 10.1001/jamaoncol.2021.4318 |
| 45 | Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer (2017) 41:125–8. | - | doi: 10.1016/j.currproblcancer.2016.12.001 |
| 46 | Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxИКТties and immunotherapy. Am J Clin Dermatol (2018) 19:345–61. | - | doi: 10.1007/s40257-017-0336-3 |
| 47 | Ma B, Anandasabapathy N. Immune checkpoint blockade and skin toxИКТty pathogenesis. J Invest Dermatol (2022) 142:951–9. | - | doi: 10.1016/j.jid.2021.06.040 |
| 48 | Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M. Dermatologic toxИКТties to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol (2020) 83:1130–43. | - | doi: 10.1016/j.jaad.2020.04.105 |
| 49 | Patil PA, Zhang X. Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med (2021) 145:571–82. | - | doi: 10.5858/arpa.2020-0070-RA |
| 50 | Yamada K, Sawada T, Nakamura M, Yamamura T, Maeda K, Ishikawa E, et al. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. World J Gastroenterol (2021) 27:7190–206. | - | doi: 10.3748/wjg.v27.i41.7190 |
| 51 | Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxИКТties from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol (2022) 33:1217–38. | -- | doi: 10.1016/j.annonc.2022.10.001 |
| 52 | Rajha E, Chaftari P, Kamal M, Maamari J, Chaftari C, Yeung SJ. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol Rep (Oxf) (2020) 8:25–30. | - | doi: 10.1093/gastro/goz065 |
| 53 | Wang ZH, Shen L. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med (2018) 4:1–7. | - | doi: 10.1016/j.cdtm.2017.12.001 |
| 54 | Gupta A, De Felice KM, Loftus EJ, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther (2015) 42:406–17. | - | doi: 10.1111/apt.13281 |
| 55 | Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut (2018) 67:2056–67. | - | doi: 10.1136/gutjnl-2018-316948 |
| 56 | Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother (2017) 66:581–92. | - | doi: 10.1007/s00262-017-1962-6 |
| 57 | Ascierto PA, Del VM, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol (2017) 18:611–22. |  | doi: 10.1016/S1470-2045(17)30231-0 |
| 58 | Shojaie L, Ali M, Iorga A, Dara L. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B (2021) 11:3727–39. | - | doi: 10.1016/j.apsb.2021.10.003 |
| 59 | Farshidpour M, Hutson W. Immune checkpoint inhibitors induced hepatotoxИКТty; gastroenterologists' perspectives. Middle East J Dig Dis (2022) 14:244–53. | - | doi: 10.34172/mejdd.2022.279 |
| 60 | Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol (2021) 39:4073–126. | - | doi: 10.1200/JCO.21.01440 |
| 61 | Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol (2018) 9:180. | - | doi: 10.1038/s41424-018-0049-9 |
| 62 | de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res (2019) 51:145–56. | - | doi: 10.1055/a-0843-3366 |
| 63 | Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol (Lausanne) (2022) 13:1010279. | - | doi: 10.3389/fendo.2022.1010279 |
| 64 | Tachibana M, Imagawa A. Type 1 diabetes related to immune checkpoint inhibitors. Best Pract Res Clin Endocrinol Metab (2022) 36:101657. | - | doi: 10.1016/j.beem.2022.101657 |
| 65 | Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis. Diabetes Med (2019) 36:1075–81. | - | doi: 10.1111/dme.14050 |
| 66 | Zheng Z, Liu Y, Yang J, Tan C, Zhou L, Wang X, et al. Diabetes mellitus induced by immune checkpoint inhibitors. Diabetes Metab Res Rev (2021) 37:e3366. | - | doi: 10.1002/dmrr.3366 |
| 67 | Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist (2017) 22:709–18. | - | doi: 10.1634/theoncologist.2016-0487 |
| 68 | Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer (2017) 73:1–8. | - | doi: 10.1016/j.ejca.2016.12.001 |
| 69 | Marini A, Bernardini A, Gigli GL, Valente M, Muniz-Castrillo S, Honnorat J, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology (2021) 96:754–66. | - | doi: 10.1212/WNL.0000000000011795 |
| 70 | Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, et al. CardiotoxИКТty of immune checkpoint inhibitors. ESMO Open (2017) 2:e247. | - | doi: 10.1136/esmoopen-2017-000247 |
| 71 | Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation (2004) 109:2749–54. | -- | doi: 10.1161/01.CIR.0000130926.51766.CC |
| 72 | Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, et al. PD-1 defИКТency results in the development of fatal myocarditis in MRL mice. Int Immunol (2010) 22:443–52. | - | doi: 10.1093/intimm/dxq026 |
| 73 | Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol (2012) 188:4876–84. | - | doi: 10.4049/jimmunol.1200389 |
| 74 | Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation (2020) 142:2299–311. | - | doi: 10.1161/CIRCULATIONAHA.120.049981 |
| 75 | Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016) 387:1540–50. | - | doi: 10.1016/S0140-6736(15)01281-7 |
| 76 | Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, et al. Targeting early stages of cardiotoxИКТty from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J (2022) 43:316–29. | - | doi: 10.1093/eurheartj/ehab430 |
| 77 | Jaworska K, Ratajczak J, Huang L, Whalen K, Yang M, Stevens BK, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol (2015) 194:325–33. | - | doi: 10.4049/jimmunol.1400497 |
| 78 | Liao W, Zheng H, Wu S, Zhang Y, Wang W, Zhang Z, et al. The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis. Am J Nephrol (2017) 46:371–9. | - | doi: 10.1159/000480641 |
| 79 | Vandiver JW, Singer Z, Harshberger C. Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target Oncol (2016) 11:553–6. | - | doi: 10.1007/s11523-016-0426-9 |
| 80 | Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol (2017) 45:160–9. | - | doi: 10.1159/000455014 |
| 81 | Roberto I, Chiara C, Emanuela F, Davide B, Mario R, Antonio BP, et al. Renal toxИКТty in patients treated with anti-Pd-1 targeted agents for solid tumors. J Onco-Nephrology (2017) 1(2):132–142. | - | doi: 10.5301/jo-n.5000019 |
| 82 | Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, et al. FDA-Approved and emerging next generation predictive biomarkers for immune checkpoint -inhibitors in cancer patients. Front Oncol (2021) 11:683419. | - | doi: 10.3389/fonc.2021.683419 |
| 83 | Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, et al. Advances in knowledge and management of immune-related adverse events in cancer immunotherapy. Front Endocrinol (Lausanne) (2022) 13:779915. | - | doi: 10.3389/fendo.2022.779915 |
| 84 | Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol (2021) 39:4073–126. | - | doi: 10.1200/JCO.21.01440 |
| 85 | Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol (2021) 27:5376–91. | - | doi: 10.3748/wjg.v27.i32.5376 |
| 86 | Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis (2021) 80:36–48. | - | doi: 10.1136/annrheumdis-2020-217139 |
| 87 | Liu X, Wu W, Fang L, Liu Y, Chen W. TNF-alpha inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis. Front Immunol (2022) 13:922782. | - | doi: 10.3389/fimmu.2022.922782 |
| 88 | Muley SA, Jacobsen B, Parry G, Usman U, Ortega E, Walk D, et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve (2020) 61:575–9. | - | doi: 10.1002/mus.26804 |
| 89 | Chauvet E, Blanchard RG, Manel V, Delmont E, Boucraut J, Garcia-Tarodo S. Autoantibodies to a nodal isoform of neurofascin in pediatric chronic inflammatory demyelinating polyneuropathy. Child Neurol Open (2023) 10:2329048X–221149618X. | - | doi: 10.1177/2329048X221149618 |
| 90 | Verma N, Jaffer M, Pina Y, Peguero E, Mokhtari S. Rituximab for immune checkpoint inhibitor myasthenia gravis. Cureus (2021) 13:e16337. | - | doi: 10.7759/cureus.16337 |
| 91 | Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, et al. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer (2020) 8(2):e001287. | - | doi: 10.1136/jitc-2020-001287 |
| 92 | Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2014) 15:69–77. | - | doi: 10.1016/S1470-2045(13)70551-5 |
| 93 | Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, et al. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv (2022) 6:1143–51. | - | doi: 10.1182/bloodadvances.2021006240 |
| 94 | Manos K, Chong G, Keane C, Lee ST, Smith C, Churilov L, et al. Immune priming with avelumab and rituximab prior to r-CHOP in diffuse large b-cell lymphoma: the phase II AvR-CHOP study. Leukemia (2023) 37(5):1092–1102. | - | doi: 10.1038/s41375-023-01863-7 |
| 95 | Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol (2014) 6:a16295. | - | doi: 10.1101/cshperspect.a016295 |
| 96 | Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res (2015) 21:1248–57. | - | doi: 10.1158/1078-0432.CCR-14-2291 |
| 97 | Smolen JS, Landewe R, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis (2023) 82:3–18. | - | doi: 10.1136/ard-2022-223356 |
| 98 | Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med (2017) 377:317–28. | - | doi: 10.1056/NEJMoa1613849 |
| 99 | Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract (2019) 25:551–7. | - | doi: 10.1177/1078155217745144 |
| 100 | Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer (2018) 6:156. | - | doi: 10.1186/s40425-018-0481-0 |
| 101 | Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, et al. Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. J Thorac Oncol (2021) 16:318–26. | - | doi: 10.1016/j.jtho.2020.09.007 |
| 102 | Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist (2018) 23:943–7. | - | doi: 10.1634/theoncologist.2018-0028 |
| 103 | Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med (2021) 93:87–94. | - | doi: 10.1016/j.ejim.2021.07.016 |
| 104 | Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, et al. Serum interleukin-6 and c-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer (2020) 8(1):e000842. | - | doi: 10.1136/jitc-2020-000842 |
| 105 | Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med (2021) 385:142–52. | - | doi: 10.1056/NEJMoa2102383 |
| 106 | Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis (Auckl) (2022) 12:127–37. | - | doi: 10.2147/PTT.S367744 |
| 107 | Merola JF, Landewe R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2023) 401:38–48. | - | doi: 10.1016/S0140-6736(22)02303-0 |
| 108 | Esfahani K, Miller WJ. Reversal of autoimmune toxИКТty and loss of tumor response by interleukin-17 blockade. N Engl J Med (2017) 376:1989–91. | - | doi: 10.1056/NEJMc1703047 |
| 109 | Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: from mechanism to autoimmune therapy. Int Immunopharmacol (2020) 80:106221. | - | doi: 10.1016/j.intimp.2020.106221 |
| 110 | Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev (2009) 229:307–21. | - | doi: 10.1111/j.1600-065X.2009.00780.x |
| 111 | Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U.S.A. (2002) 99:3013–7. | - | doi: 10.1073/pnas.042684699 |
| 112 | Scarsi M, Paolini L, Ricotta D, Pedrini A, Piantoni S, Caimi L, et al. Abatacept reduces levels of switched memory b cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol (2014) 41:666–72. | - | doi: 10.3899/jrheum.130905 |
| 113 | Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs (2017) 77:1221–33. | - | doi: 10.1007/s40265-017-0775-4 |
| 114 | Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology (2008) 71:917–24. | - | doi: 10.1212/01.wnl.0000325915.00112.61 |